BAY 11-7082

Catalog No.S2913 Synonyms: BAY 11-7821

BAY 11-7082 Chemical Structure

Molecular Weight(MW): 207.25

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Size Price Stock Quantity  
In DMSO USD 120 In stock
USD 90 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

7 Customer Reviews

  • Immunofluorescence images of Ishikawa cells showing the increase in the nuclear colocalization of ERa (red) and p65 (green) after E2 incubation. Nuclear colocalization is yellow. Treatment with ICI 182,780, PDTC or Bay inhibited the nuclear localization of both ERa and p65. Blue, DAPI-stained nuclei. All pictures were obtained the same day using the same microscope settings. Original magnification 3200, bar =50 um. Arrows, cytoplasmic ERa and p65 staining. ICI, ICI 182,780; Bay, Bay 11-7082.

    Int J Cancer 2014 135(2), 282-94. BAY 11-7082 purchased from Selleck.

    The inhibition of IκBα phosphorylation by BAY11-7082 (10 µM) was confirmed using western blotting, and GAPDH was used as an internal reference.

    Cancer Lett, 2016, 378(2):131-41. BAY 11-7082 purchased from Selleck.

  • The effect of vaspin on TNF α -induced THP-1 cell adhesion to HAECS measured staining with VibrantDiO® Cell-Labeling Solution. The level of THP-1 cell adhesion to HAECs was measured at 4 hr after treatment with 25 -100 ng/mL vaspin in the presence or absence of 10 ng/mL TNF α . BAY11-7082 (10 uM, S2913, Selleckchem, USA), an inhibitor of NF- κ B, was used as a positive control.

    Cardiovasc Diabetol 2014 13, 41. BAY 11-7082 purchased from Selleck.

    J Neurochem, 2018, 144(6):780-790. BAY 11-7082 purchased from Selleck.

  • Shown are Western blot analysis of Wnt5a expression in HDPCs treated with TNF-a (n=3–4). The gene expression level was normalized to GAPDH (n = 3–6). HDPCs were preincubated with pyrrolidinedithiocarbamic acid (PDTC, an NF-κB inhibitor), BAY11-7082 (an NF-κB inhibitor), SP600125 (a JNK inhibitor), SB203580 (a p38 inhibitor), or U0126 (an ERK inhibitor) before treatment with TNF-a.

    J Biol Chem 2014 289(30), 21028-21039. BAY 11-7082 purchased from Selleck.

    The irradiated Beas-2B cells were further co-cultured with U937 cells for 24 h after irradiation. In some experiments, Beas-2B cells were pretreated with 10 μM of U0126, SB203580, or necrostatin-1 for 1 h before irradiation, U937 cells were pretreated with 10 μM BAY 11-7082 1 h prior to cell co-culture, or 1 μg/ml anti-TNF-a antibody, 2 μg/ml anti-IL-8 antibody,40 nM SB225002 were added to the medium in the cell co-culture period. ***P < 0.001 compared with the non-irradiation control. #P < 0.05 ##P < 0.01 compared with cor-responding -irradiated cells.

    Mutation Research, 2016, 789:1-8. BAY 11-7082 purchased from Selleck.

  • Reverse transcription-quantitative polymerase chain reaction assays revealed the effect of atorvastatin on visfatin-induced inflammation. Human coronary artery endothelial cells were incubated in the absence or presence of 50 ng/ml visfatin, with or without 50 nM FK866, 50 µM BAY11-0782 or 10 µM atorvastatin, for 24 h. (A) Atorvastatin downregulated visfatin-induced IL-6 gene expression (P-values from left to right vs. control: 0.0081, 0.0045, 0.0233 and 0.0057). (B) Atorvastatin decreased visfatin-induced IL-8 gene expression (P-values from left to right vs. control: 0.0096, 0.0037, 0.0043 and 0.0031). (C) Atorvastatin downregulated visfatin-induced IL-6 release (P-values from left to right vs. control: 0.0078, 0.0022, 0.0783 and 0.0382). (D) Atorvastatin inhibited visfatin-induced IL-8 release (P-values from left to right vs. control: 0.0094, 0.0032, 0.0039 and 0.0035). Significant differences were determined using Student's t-test; *P<0.05, **P<0.01 vs. visfatin control. IL-6, interleukin-6; IL-8, interleukin-8.

    Oncol Lett, 2016, 12(2):1438-1444. BAY 11-7082 purchased from Selleck.

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Biological Activity

Description BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.
Targets
E2-conjugating enzymes [6]
(Cell-free assay)
IκBα phosphorylation [1]
(Tumor cells)
10 μM
In vitro

BAY 11-7082 completely and specifically abrogates NF-κB DNA binding, downregulating the NF-κB-inducible cytokine IL-6 and inducing apoptosis. [1] BAY 11-7082 (< 8 μM) is able to effectively inhibit both basal and TNFα stimulated NFκB luciferase activity in a dose dependent manner. BAY 11-7082 (8 μM) strongly inhibits the rate of proliferation in NCI-H1703 cells. [2] Bay 11-7082 (5 μM) rapidly and efficiently reduces the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulates the expression of the antiapoptotic gene, Bcl-x(L), whereas it has little effect on the DNA binding of another transcription factor, AP-1. Bay 11-7082-induced apoptosis of primary ATL cells is more prominent than that of normal peripheral blood mononuclear cells, and apoptosis of these cells is also associated with down-regulation of NF-kappaB activity. Bay 11-7082 (5 μM) selectively induces apoptosis of HTLV-I–infected T-cell lines associated with down-regulation of the expression of cyclin D1, cyclin D2, and Bcl-xL. [3] BAY 11-7082 (100 μM) prevents the nuclear translocation of p65 elicited by NMDA and the NMDA-induced increase of NF-κB binding in mouse hippocampal slices. BAY 11-7082 prevents NMDA toxicity occurring in CA1 region of hippocampal slices with 40% neuroprotection at 20 μM and 70% neuroprotection at 100 μM. [4] BAY 11-7082 at all concentrations tested significantly inhibits NF-κB p65 DNA-binding activity in adipose tissue, whereas in skeletal muscle, BAY 11-7082 at 50 μM and 100 μM significantly inhibits NF-κB p65 DNA-binding activity. BAY 11-7082 (100 μM) reduces IKK-β protein in human adipose tissue and skeletal muscle. BAY 11-7082 (100 μM) significantly decreases the release of TNF-α from adipose tissue, whereas the release of IL-6 and IL-8 is significantly inhibited at all concentrations of BAY 11-7082 tested. BAY 11-7082 (50 μM) significantly decreases the release of TNF-α, IL-6, and IL-8 in skeletal muscle. [5] BAY 11-7082 is also found to inactivate the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex), and thus induces B-cell lymphoma and leukaemic T-cell death. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa NXy3SmVNTnWwY4Tpc44hSXO|YYm= MYWxNOKh|ryP MWqxMlUhcA>? NEjrOYRi[m:uaYPo[ZMhSlCDIHnu[JVk\WRidYCgdoVofWyjdHnvckBw\iCITjDhcoQhVU2SLUpCpC=> NFHKRlAzPTd7N{SzOy=>
SiHa  M1i5dWZ2dmO2aX;uJGF{e2G7 M320NVExyqEQvF2= MUSxMlUhcA>? MkX2ZYJwdGm|aHXzJGJRSSCrbnT1Z4VlKHWyIILl[5Vt[XSrb36gc4YhTk5iYX7kJG1OWC17wrC= MUCyOVc6PzR|Nx?=
ARPE-19 M2jsemZ2dmO2aX;uJGF{e2G7 MoX4NUDPxE1? MUmwMlUhcA>? NFLleoR{fXCycnXzd4V{KFSJLXnu[JVk\WUEoFnMMVjDqHC{b33veIVzKGGldHn2ZZRqd25? NGrQTGEzPTV7M{CyPS=>
HCT116 NXjlTGdUTnWwY4Tpc44hSXO|YYm= MnHuOUDPxE1? NUG4N|RtOiCq MnToSG1UVw>? MWDheJRmdnWjdHXzJJNqdHmvYYLpck1qdmS3Y3XkJIRwf26{ZXf1cIF1cW:wIH;mJIN6[2yrbjDENS=> MYqyOVQ4QTd{Mx?=
HMECs MoXRSpVv[3Srb36gRZN{[Xl? NGDGXWY2yqEQvF2= NHX4S4YzKGh? MUjhZo9tcXOqZYOgWG5HNc7zLXnu[JVk\WRiVlPBUU0yKGW6cILld5Nqd28EoB?= NIL3VlUzPTF7M{GxOi=>
A549  M4nPUmZ2dmO2aX;uJGF{e2G7 M4[5c|Ex6oDLwsXN M3XZR|EzKGh? M1ey[ZN2eHC{ZYPz[ZMhTH[uLUOgbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKHB4NR?= NX;NW4JVOjVzNU[4NFA>
RAW 264.7 NYTVb2dCTnWwY4Tpc44hSXO|YYm= Ml\FOeKh|ryP NH;OZVIyKGh? NXvX[ZFEcW6qaXLpeJMhXE6ILd8xJIFv\CCLTD2xNkBxPDBicILv[JVkfGmxbh?= M1f1[FI2ODF7NU[3
macrophages M4fvXGZ2dmO2aX;uJGF{e2G7 NFvWNZI2KML3TR?= MoDvN{Bp MmfxdIFzfGmjbHz5JIJtd2OtczDZVGZUNWmwZIXj[YQh\XiycnXzd4lwdiCxZjDpUm9UKGGwZDDDU3guOsLi MlzTNlQ6Pjd6OUi=
HUVECs NY\PNpI4TnWwY4Tpc44hSXO|YYm= M4XvUVMuOzBizszN M4PtTVEhcA>? NGXaNWRz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJI1qWi1zNE\hJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYPTPYJxOjR6NkO5OlU>
HeLa  MmW5SpVv[3Srb36gRZN{[Xl? MnnaOeKh|ryP NHuyN2wzPCCq MnXkSG1UVw>? MU\y[YR2[2W|IITo[UBi[3Srdnn0fUBw\iCWTl[t{tEheHKxbX;0[ZLDqA>? M{D5O|I1PjV5N{iz
A549 M2DL[GZ2dmO2aX;uJGF{e2G7 M2LkfFExKM7:TR?= MV[x5qCKcA>? NHnmTHBqdmirYnn0d{B1cGViaX7jdoVie2Vib3[gdIhwe3Cqbz3J{tpD|rFiaX6gVGEyODNvaX7m[YN1\WRiY4XseJVz\XQEoB?= MVKyOFYyOjR6OB?=
HUVEC M2roWmZ2dmO2aX;uJGF{e2G7 MYOyNEDDvU1? NHrzOI0xNjViaB?= MmTiSG1UVw>? MUPwdoV3\W62czD0bIUhcW6mdXP0bY9vKG:oIFXBUUBmgHC{ZYPzbY9v NUjxXJhTOjR3NUGyNFk>
A549RT-eto MnTVRZBweHSxc3nzJGF{e2G7 NV7SOmNsOTEEoN88US=> NV\iWolyOjRiaB?= NXzlW5EzTE2VTx?= NGK5R21i[2OnbHXyZZRmeyCIRWLPMY1m\GmjdHXkJIFxd3C2b4Ppdy=> MnvVNlQ2OzVyOEO=
THP-1  MlXTSpVv[3Srb36gRZN{[Xl? M3rZ[VAvOS9zwrFOwG0> MofaNE42KGh? MlrxZYJzd2ejdHXzJHRPTi4QsTDz[YNz\XSrb36gZZMhf2WubDDhd{B1cGViaX7jdoVie2WmIIPlZ5JmfGmxbjDv[kBKVC14IHHu[EBKVC1zzsK= Ml\HNlQ{Pzh3M{[=
SKCXCR2  MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTKNkDDvU1? NFTVZVM1QCCq MlTD[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvckB{cWewaX\pZ4FvfGy7 NYHRdZBqOjR|N{[3OFc>
SKCXCR2  NVnNSmtjTnWwY4Tpc44hSXO|YYm= MUeyJOK2VQ>? MV60PEBp MWficI9kc3NidHjlJGNZS0xzLXnu[JVk\WRiY3XscEBqdn[jc3nvci=> Mn;HNlQ{PzZ5NEe=
OVCXCR2 M1vDXWZ2dmO2aX;uJGF{e2G7 M2TISVIhyrWP MkPxOFghcA>? NGPFRVNjdG:la4OgeIhmKEO[Q1yxMYlv\HWlZXSgZ4VtdCCrbo\hd4lwdg>? M4Hy[FI1Ozd4N{S3
DSCs  MVrGeY5kfGmxbjDBd5NigQ>? NWT5e|BFOi53IN88US=> MU[wMlUhcA>? NXH4WVJZemW4ZYLz[ZMhfGinIHXubIFv[2WvZX70JI9nKEOFTEKvR2NTOiCneIDy[ZN{cW:wIH;mJGRUS3NiaX7keYNm\CCkeTDJUE0{Ow>? MYSyOFM1PDJ2MB?=
WPs M3m2fmZ2dmO2aX;uJGF{e2G7 NFfh[oMzPSEQvF2= NYr4XGZ6PSCvaX6= MYnzeZBxemW|c3XzJGFVWCCjbnSgendHKHOnY4LleIlwdg>? M{XCV|I1OzNzMkC3
A549RT-eto MVjBdI9xfG:|aYOgRZN{[Xl? NGjFdoIyOMLizszN M2TyZ|I1KGh? Ml;iZYNk\WyncnH0[ZMhTjF2IHX4eJJi[3RvbXXkbYF1\WRiYYDvdJRwe2m|IHPvcYJqdmWmIITy[YF1dWWwdDD3bZRpKEZzNB?= NFjLZZczPDJ{MEeyOS=>
A549RT-eto M1z3XmZ2dmO2aX;uJGF{e2G7 NHjiZpYyOMLizszN MXOyOEBp NG\Jc5dl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wy|IH;mJG5HNc78QjDhcoQhWC2pcNMg M{nQSVI1OjJyN{K1
FaDu NIriXVFHfW6ldHnvckBCe3OjeR?= NV[yPZVHOiCq MlfmbY5pcWKrdIOgdFY2KGW6cILld5Nqd25iYX7kJIJtd2OtczDUUmbPuS2rbnT1Z4VlKFSZSWPUJIV5eHKnc4Ppc44> Mn7ENlQzOjB4MkK=
IVD  MWrGeY5kfGmxbjDBd5NigQ>? NXjXNFlvOTEEoN88US=> MoPsN{Bl Mor1doV3\XK|ZYOgWG5HNc7z4pETcYVlcWG2ZXSgd5VxeHKnc4Ppc44hd2ZidHjlJIRqe2NibXH0dol5KG2jY4LvcY9t\WO3bHXzJIFo\3KnY3HuJIFv\CClb3zsZYdmdiCLSR?= NInGeVIzPDF5NkiwPC=>
IVD  M3;KVmZ2dmO2aX;uJGF{e2G7 NUS1WVhSOTEEoN88US=> NFTFcW0{KGR? MWPhZpJw\2G2ZYOgWG5HNc7z4pETbY5lfWOnZDD1dE1z\We3bHH0bY9vKG:oIFHERW1VWy12IHHu[EBCTEGPVGOtOeKh M2jPcVI1OTd4OEC4
iNKT NV;0R4pMTnWwY4Tpc44hSXO|YYm= MYSxNE8yODBizszN MUGwMlUhcA>? MoLWbY5pcWKrdIOgeIhmKGmwZIXjeIlwdiCxZjDBNmFTKG2UTlGgZY5lKG:2aHXyJIZi[3Sxch?= M2fB[|I1OTJ2NEWz
PC-3 NIW2eHFHfW6ldHnvckBCe3OjeR?= NE[2WIUzNjVxNT:xNEDPxE1? M1z3fVAvPSCq M2rPbIJtd2OtczDJS2YuUUlvaX7keYNm\CCVVGOgcXJPSSCneIDy[ZN{cW:wwrC= M1rGU|I1ODV3NUKw
THP-1  MnrISpVv[3Srb36gRZN{[Xl? NVPQOlRDOTEEoN88US=> NHzKXJAyyqCq M4T3SYFjd2yrc3jld{B1cGViZX\m[YN1KG:oIILIV3AzPyCxbjDTVk1CKG2UTlG= M4i4XFI{QTN7M{m4
A549 MYTGeY5kfGmxbjDBd5NigQ>? MUOxxsDPxE1? NV7ORo1RPDhiaB?= NVyxNmE3\W6qYX7j[ZMhfGinIIXwMZJm\3WuYYTpc44hd2ZiSd86RkBidmRic4Xid4VyfWWwdDDk[YNz\WG|ZTDpckBD[XhiZYjwdoV{e2mxbjDpcoR2[2WmIHL5JINwdWKrbnXkJJN1cW23bHH0bY9v NVjVNWN6OjN7MECwPFA>
A549 NV7QNXBOSXCxcITvd4l{KEG|c3H5 NV\iOmo4OcLizszN M17tXVQ5KGh? M2GwUpJm\HWlZYOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDjc41jcW6nZDDzeIlufWyjdHnvci=> NX31NY9kOjN7MECwPFA>
NCI-N87 M{P0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvmSXQyOTBxMkCvN|Ah|ryP M3[w[|YwOjRiaB?= NYj3W5p3e3WycILld5NmeyClZXzsJJZq[WKrbHn0fUB{cWewaX\pZ4FvfGy7 NILQSoEzOzh2NkW0OS=>
AGS NXnxW5hpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnER3NHOTBxMkCvN|Ah|ryP MUe2M|I1KGh? M3zCcJN2eHC{ZYPz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MVmyN|g1PjV2NR?=
MGC80-3 NHmzcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzwNXBKOTBxMkCvN|Ah|ryP MkPzOk8zPCCq MknGd5VxeHKnc4Pld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MWGyN|g1PjV2NR?=
HGC-27  MXXGeY5kfGmxbjDBd5NigQ>? MV[3MlUwOTVxM{Cg{txO MYW2JIg> NIX5U|NqdmS3Y3XzJJRp\SCmZYDoc5NxcG:{eXzheIlwdiCjbnSgeZAuemWpdXzheIlwdiCxZjDJ{tpD|rF? NIjF[2ozOzh2NkW0OS=>
MGC80-3 MXLGeY5kfGmxbjDBd5NigQ>? M1vvR|cvPS9zNT:zNEDPxE1? NFHMTow3KGh? MWnpcoR2[2W|IITo[UBl\XCqb4PwbI9zgWyjdHnvckBidmRidYCtdoVofWyjdHnvckBw\iCLzsrC{tE> NFr4T3IzOzh2NkW0OS=>
HGC-27  NX20N|NlSXCxcITvd4l{KEG|c3H5 MlrNO{42NzF3L{OwJO69VQ>? M2\wbFYhcA>? Mo[1bY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFHySXkzOzh2NkW0OS=>
HBE  NGPUSYVHfW6ldHnvckBCe3OjeR?= NFXUbGUyOM7:TR?= M2PMblNp M3HXTYFjd2yrc3jld{B1cGViaX7jdoVie2W|IH;mJGlNNTZiZYjwdoV{e2mxbjDpcoR2[2WmIHL5JGNUTQ>? Mlj6NlM5OjRyOEm=
HepG2 NILCS5dHfW6ldHnvckBCe3OjeR?= MX:wMlMwOS9|IN88US=> NXzORphSPDhiaB?= NFqyXJBz\WS3Y3XzJGlNPi2rbnT1Z4VlKFCRTkGg[ZhxemW|c3nvci=> MmnsNlM4QTF6M{O=
THP-1 MmPwSpVv[3Srb36gRZN{[Xl? NIjFU2I2KML3TR?= Mn\LNUBp Mn;OSG1UVw>? M1rDUolvcGmkaYTzJG1VSi2rbnT1Z4VlKE6IzsrCJIFkfGm4YYTpc44> Mn23NlM3OzR{MUi=
THP-1  MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPG[Wo2KML3TR?= NILQSoQ1NzhiZB?= NFfHWGRFVVOR NEXkRmNz\WS3Y3XzJJRp\SC4aXHibYxqfHlib3[gbY51emGlZXzseYxiesLiTWTC NVjIUpo3OjN4M{SyNVg>
MDM M4HhdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO1JOK2VQ>? MWi0M|gh\A>? NVTUN3JETE2VTx?= NIfMWpZz\WS3Y3XzJJRp\SC4aXHibYxqfHlib3[gbY51emGlZXzseYxiesLiTWTC NXrEclEyOjN4M{SyNVg>
AM NG\Ib3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2yfHkyPSEEtV2= MoXIOE85KGR? NUDQ[VBFTE2VTx?= M1XBeJJm\HWlZYOgeIhmKH[rYXLpcIl1gSCxZjDpcpRz[WOnbHz1cIFzyqCPVFK= Mnj4NlM3OzR{MUi=
RAW 264  MonxSpVv[3Srb36gRZN{[Xl? MV[wMlIuPSEEtV2= Ml3aN|AwPjBxOUCgcYlv M3fafIlvcGmkaYTzJJRp\SCyaH;zdIhifGG|ZTDhZ5Rqfmm2eTDv[kBRXFBzQtMg NEnZbo8zOzV5OEOwNi=>
HUVEC M1X0dWZ2dmO2aX;uJGF{e2G7 NFjHNooyOMLizszN MX[wMlUhcA>? MljuSG1UVw>? M4fR[INwfW62ZYLhZ5RmeyC2aHWgcI9{eyCxZjDUbYUzKG2UTlG= NVu1SolvOjN3NkO2N|I>
HT29 MmqzSpVv[3Srb36gRZN{[Xl? NEHiW2IyOC9|MD:xNFAh|ryP NGPZc4gyKGh? NGPaZ5ZqdmirYnn0[ZMh[m:2aDDUW2VCUy2rbnT1Z4VlKHBzMECgdJJw[2W|c3nu[y=> M2fZTVI{PTJ5MUW0
HT29 NVHGcGhETnWwY4Tpc44hSXO|YYm= M1jXXlExNzNyL{GwNEDPxE1? M3v2bFEhcA>? MUPpcohq[mm2czDUUmYucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gZY5lKGSnZ4Lh[IF1cW:wIH;mJGnPwkMQsR?= NHe5OXUzOzV{N{G1OC=>
MM.1S MkTvRZBweHSxc3nzJGF{e2G7 NXXRR5N3OzBiwsXN M1rJWFMhcA>? M2nxZ4lv\HWlZYOgUW0h[2WubDDk[YF1cCCrbo\vcJZmeyCwZXPyc5Nqew>? M2mxPFI{PTJ5MUW0
KMS-12-BM MmXlRZBweHSxc3nzJGF{e2G7 MUizNEDDvU1? MX6zJIg> NIHrfI5qdmS3Y3XzJG1OKGOnbHyg[IVifGhiaX72c4x3\XNibnXjdo9{cXN? MWCyN|UzPzF3NB?=
BAFs M3TjcmZ2dmO2aX;uJGF{e2G7 M1zZdlAvPS9zwrFOwG0> NEP4eVMzPCCq MUjpcohq[mm2czDUUmbPuS:GRWigbY5lfWOnZDDDXXAyQUFzwrD0doFve2O{aYD0dy=> M{LuRVI{PDh3NEW3
SP6.5 MmLFSpVv[3Srb36gRZN{[Xl? M1zad|Uh|ryP MojnNkBp Ml\1[IVkemWjc3XzxsB1emGwc3zvZ4F1cW:wIH;mJJA3PSCrbjD0bIUhdnWlbHX1d:Kh NFvQd|QzOzR2M{C4Oi=>
VUP M3\SbGZ2dmO2aX;uJGF{e2G7 MYG1JO69VQ>? MY[yJIg> M3:0bYRm[3KnYYPld:KhfHKjboPsc4NifGmxbjDv[kBxPjViaX6geIhmKG63Y3zleZPDqA>? M2ntRlI{PDR|MEi2
OCM1 MlG3SpVv[3Srb36gRZN{[Xl? NIG4Z2Y2KM7:TR?= Mn:wNkBp NEHZXHhl\WO{ZXHz[ZPDqHS{YX7zcI9k[XSrb36gc4YheDZ3IHnuJJRp\SCwdXPs[ZV{yqB? NIS1[lEzOzR2M{C4Oi=>
OM431 MWDGeY5kfGmxbjDBd5NigQ>? MoLFOUDPxE1? M1zrPVIhcA>? NV7uOZBj\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8Li MUmyN|Q1OzB6Nh?=
SP6.5 NEjpSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2yMlUuOjBizszN MoTqNlQhcMLi NXfGd3dzUUN3ME21JO69VSxiZYjobYJqfHNic4Tyc45oKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5R{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NH\MZY4zOzR2M{C4Oi=>
VUP NGDsNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfyNVczNjVvMkCg{txO NGnEOGIzPCCqwrC= MnLUTWM2OD13IN88UUwh\XiqaXLpeJMhe3S{b37nJIFvfGlvcILvcIln\XKjdHn2[UBm\m[nY4TzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{fYSFI{PDR|MEi2
OCM1 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\yNk42NTJyIN88US=> NUO3RVJrOjRiaNMg NUX2TWFVUUN3ME21JO69VSxiZYjobYJqfHNic4Tyc45oKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5R{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEHwdlgzOzR2M{C4Oi=>
OM431 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ToSVIvPS1{MDFOwG0> M3;aO|I1KGkEoB?= NHHFTVZKSzVyPUWg{txONCCneHjpZol1eyC|dILvcoch[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeJMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXGyN|Q1OzB6Nh?=
SP6.5 NXrB[YpUSXCxcITvd4l{KEG|c3H5 MlfkOUDPxE1? M3PyfFI1KGkEoB?= M2LLNolv\HWlZYOgZZBweHSxc3nzxsA> MoHmNlM1PDNyOE[=
VUP NUPRdll2SXCxcITvd4l{KEG|c3H5 NVz4XWZnPSEQvF2= MXmyOEBpyqB? M1zBdIlv\HWlZYOgZZBweHSxc3nzxsA> MofLNlM1PDNyOE[=
OCM1 MoPzRZBweHSxc3nzJGF{e2G7 NEnSfZk2KM7:TR?= NFPL[3YzPCCqwrC= NX3TSmJMcW6mdXPld{BieG:ydH;zbZPDqA>? MmLQNlM1PDNyOE[=
OM431 M2T4eWFxd3C2b4Ppd{BCe3OjeR?= NXTHWpN3PSEQvF2= NVflfnhROjRiaNMg NFr1XHdqdmS3Y3XzJIFxd3C2b4Ppd:Kh MUeyN|Q1OzB6Nh?=
SP6.5 NIG0RplHfW6ldHnvckBCe3OjeR?= MkfNOUDPxE1? NH\Le2oyOiCq NFLYPYdz\WS3Y3XzJJRp\SCvaXfyZZRqd28EoB?= Ml[xNlM1PDNyOE[=
VUP M2jndmZ2dmO2aX;uJGF{e2G7 Mo\wOUDPxE1? MlqxNVIhcA>? MYny[YR2[2W|IITo[UBucWe{YYTpc47DqA>? NF3BXnYzOzR2M{C4Oi=>
OCM1 NWThVGlsTnWwY4Tpc44hSXO|YYm= MYG1JO69VQ>? MYexNkBp Mn;ZdoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? MkDXNlM1PDNyOE[=
OM431 NGnRT2hHfW6ldHnvckBCe3OjeR?= M1XuSlUh|ryP NX[zVGtIOTJiaB?= MojZdoVlfWOnczD0bIUhdWmpcnH0bY9vyqB? NFjZS4wzOzR2M{C4Oi=>
HBL-1  NYH5[mRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPseGVTO8LizszN MoHsNlQwPDhxN{KgbC=> NV3Vc|dSTE2VTx?= MlrFd4xwf3NiY3XscEBoem:5dHigcY9l\XO2bIm= MVOyN|Q1OTd|MB?=
RAW 264.7 NHqybGtHfW6ldHnvckBCe3OjeR?= NIXrT5QzNTF3IN88US=> MmW2NUBp NFHLe2xFVVOR MXnzeZBxemW|c3XzJJRp\SCjY4TpeoF1cW:wIH;mJGlMUyCoYX3pcJkhdWWvYnXydy=> MXmyN|Q1OTd|MB?=
IL-1R  NIXRe4pHfW6ldHnvckBCe3OjeR?= Mlq1Nk0yPSEQvF2= M4fKNlEhcA>? NV;Fe4lETE2VTx?= NYD2eWZXe3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCLS1ug[oFucWy7IH3lcYJmenN? MoO0NlM1PDF5M{C=
RAW 264.7 MXTGeY5kfGmxbjDBd5NigQ>? MnTNNVUh|ryP NXe2fXhmOSCq MkHUSG1UVw>? M1\IdJN2eHC{ZYPz[ZMhfGinIHHjeIl3[XSrb36gc4Yh[W6mIFrOTy=> NW\XNI9IOjN2NEG3N|A>
IL-1R  MVnGeY5kfGmxbjDBd5NigQ>? M4DaPVE2KM7:TR?= NV;PVW17OSCq M2m0RmROW09? NFyxSo9{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKGGwZDDKUms> NVjiZVRqOjN2NEG3N|A>
U2OS NVvT[4ZXTnWwY4Tpc44hSXO|YYm= M1rSNlE2KM7:TR?= MnG2NUBp MlHBSG1UVw>? MXXwdoV3\W62czD0bIUhVFCVLTDvdkBKVC1zLYP0bY12dGG2ZXSg[o9zdWG2aX;uJI9nKEt4Mz3wWYIh[2ijaX7zxsA> M1:1OVI{PDRzN{Ow
MT‐1  NXvJRW5nTnWwY4Tpc44hSXO|YYm= MkO3POKhyrWv NVnrZ283OyCq M3XB[IRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIIFihLBUXEGWMzDhcoQheOLCkETFRnAy M1\xOVI{Ojd6NEe5
MT‐2  NFPGcW1HfW6ldHnvckBCe3OjeR?= NF\Rd5M5yqEEtX2= NY\1ZWM6OyCq NUHUUnV3\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdQKBmFOWQWSzJIFv\CCy4pEQOGVDWDF? NIe4Rm8zOzJ5OES3PS=>
MT‐1  MlnwSpVv[3Srb36gRZN{[Xl? NXHrdVg6QMLiwsXt NV\TeW4xOyCq Mmrs[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJJA3PSC|dXL1col1KG:oIF7G5qCR|rqEwrC= NUPIeXh4OjN{N{i0O|k>
MT‐2  MmXjSpVv[3Srb36gRZN{[Xl? MlrQPOKhyrWv NY\2UJFEOyCq MmPl[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJJA3PSC|dXL1col1KG:oIF7G5qCR|rqEwrC= NHzpT4EzOzJ5OES3PS=>
MCF-7  M{LyPWZ2dmO2aX;uJGF{e2G7 MnHaNk42NTF3IN88US=> M{f2RlAvPSCq NYX2SI1HTE2VTx?= NYrnSHRn[2G3c3XzJJRp\SCpcnHkeYFtKGyxc4Ogc4Yh[2WubDDh[Ihme2mxbh?= MmXjNlMxQTN{Mke=
HaCaT  NEThNZBHfW6ldHnvckBCe3OjeR?= NU\sTVBZPS5ywrFOwG0> M3fQZ|HDqGkEoB?= M3jv[4F1fGWwdXH0[ZMhfGinIGTDU2gucW6mdXPl[EBxem:mdXP0bY9vKG:oIFnMMVbDqA>? Mk[5NlMxPDFzNki=
A549  NGHJSpdHfW6ldHnvckBCe3OjeR?= MV6xJIg> MVPpcohq[mm2czDMWGEucW6mdXPl[EBUWC2DIH3SUmEheHKxZIXjeIlwdsLic3nncolncWOjboTsfS=> MYiyN|A{OTJzMx?=
OA chondrocytes  MUDGeY5kfGmxbjDBd5NigQ>? MorONVAh|ryP MnTsNUBp MkO3Zoxw[2u|IITo[UBCT0VvQmPBMYlv\HWlZXSg[4Vv\S:ycn;0[YlvKGW6cILld5Nqd25ib3[gS3JRPzhib4KgR29ZNTJiKIC8NE4xPSl? MU[yNlk5OjJ{OB?=
RAW264.7 NUXWSJJUTnWwY4Tpc44hSXO|YYm= MXuxOUDPxE1? MlfJNVUuOTJyIH3pci=> MYnicI9kc3NidHjlJJBzd2S3Y4Tpc44hd2ZiTl:sJHBITTJuIHHu[EBVVkZvzsG= Ml\FNlI4PDV3MkO=
RAW264.7 M4nHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\2OU0{OCEQvF2= MWqyOEBp MoHPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXSyNlc1PTV{Mx?=
HBL6 M1jDNmFxd3C2b4Ppd{BCe3OjeR?= MVWwMlUwPS9{NTFOwG0> NWfVcG5CPi9{NDDo NH;hU|hl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZY5lKGynZXHkd{B1dyCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= M2PQPVIzODd2OEKw
HT29  MV;GeY5kfGmxbjDBd5NigQ>? Mm\0NU0yOCEQvF2= M{fnc|ExyqCq MXXpcoNz\WG|ZYOgTG8uOSCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MVGyNVYzODl4NB?=
Ca9–22 M2fyUWFxd3C2b4Ppd{BCe3OjeR?= MmPYNVDDqM7:TdMg NIHoc4gyKGh? NFTxRWhkd22ybHX0[Yx6KGmwaHnibZR{KEGOQT3QSHQucW6mdXPl[EBieG:ydH;zbZM> NVXNcJVSOjFzM{i0PFA>
Ca9–22 M1H2UGZ2dmO2aX;uJGF{e2G7 M2fySVExyqEQvF5CpC=> MorxNUBp MVvjc41xdGW2ZXz5JIFjem:pYYTld{B1cGViQVzBMXBFXC2rbnT1Z4VlKEqQSzDhZ5RqfmG2aX;u Mkm0NlEyOzh2OEC=
A-549 MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LFdVExyqEQvF5CpC=> M3LhNVI1NzR6IHi= NUP5NlF4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MXWyNFg3PjB2Mx?=
AP MWnGeY5kfGmxbjDBd5NigQ>? NVj2SoJvPS9zMDFOwG0> MnfHOFghcA>? NHrCd41ld3ewcnXneYxifGW|IITo[UBDSURicILveIVqdiCuZY\lcEBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXSyNFU6PjZ2NR?=
AQ1 NETGSINHfW6ldHnvckBCe3OjeR?= NYDzbpAyPS9zMDFOwG0> NV;qcJd[PDhiaB?= Mlz4[I94dnKnZ4XsZZRmeyC2aHWgRmFFKHC{b4TlbY4hdGW4ZXygZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnzTNlA2QTZ4NEW=
AP NVPldGgzTnWwY4Tpc44hSXO|YYm= NHzGWmEzOCEQvF2= MoTsOE85KGh? NVToeWV6\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MkTpNlA2QTZ4NEW=
AQ1 MkfiSpVv[3Srb36gRZN{[Xl? MknlNlAh|ryP NWCwS|JEPC96IHi= NV\jUolY\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MlTGNlA2QTZ4NEW=
THP-1 NXjq[FFCTnWwY4Tpc44hSXO|YYm= NEf3ZnA2yqEQvF5CpC=> MnznNE42KGh? NHOxTZFifHSnboXheIV{KHSqZTDMVHMucW6mdXPl[EBxNUoQulNOtUBxem:2ZXnuJIJ6KDd{JR?= NV2xRmxKOjB|MEm3NVg>
K562 NV7DTIVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTqNk0{OCEQvF2= MluyNlQhcA>? MV;JR|UxRThizszNMIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFjPNIwyQTZ2NkiwOy=>
Jurket MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqyMVMxKM7:TR?= NUHwOnFVOjRiaB?= NUPrcHFDUUN3ME23MlEh|ryPLDDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NUfuW5llOTl4NE[4NFc>
U937 MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGKzUZEzNTNyIN88US=> NELaPJQzPCCq MWfJR|UxRTFyLkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mki5NVk3PDZ6MEe=
PBMC M{LRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[3Nk0{OCEQvF2= MVqyOEBp M4Xxd2lEPTB;NECuNkDPxE1uIHnubIljcXS|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXexPVY1PjhyNx?=
K562 NYT5VGJnSXCxcITvd4l{KEG|c3H5 NGnJOW4zNTJywrFOwG3DqA>? NXW2TodCOjRiaB?= Mmr2bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHHwc5B1d3Orcx?= Mn\jNVk3PDZ6MEe=

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: NCI-H1703 cells
  • Concentrations: ~8 μM
  • Incubation Time: 12 hours
  • Method: Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 41 mg/mL (197.82 mM)
Ethanol 10 mg/mL (48.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 207.25
Formula

C10H9NO2S

CAS No. 19542-67-7
Storage powder
in solvent
Synonyms BAY 11-7821

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

IκB/IKK Inhibitors with Unique Features

Related IκB/IKK Products4

Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID